BONE GRAFTS USING BIOLOGICAL BONE

Brand	Owner (click to sort)	Address	Description
S.M.A.R.T.BONEGRAFT	Ernesto A. Lee, D.M.D., P.C.	976 Railroad Ave., Suite 200 Bryn Mawr PA 19010	Bone grafts using biological bone tissue for reconstruction of the jaw, including xenografts for use in reconstruction of the jaw;SMART BONE GRAFT;Synthetic bone grafts for reconstruction of the jaw; surgical instruments for use in jaw reconstruction surgery, including surgical instruments for utilization to prepare a site in the jaw for a dental implant and for use in implanting a xenograft or biomaterial in the jaw;
S.M.A.R.T.NEW ATTACHMENT	Ernesto A. Lee, D.M.D., P.C.	976 Railroad Ave., Suite 200 Bryn Mawr PA 19010	Bone grafts using biological bone tissue for reconstruction of the jaw, including xenografts for use in reconstruction of the jaw;SMART NEW ATTACHMENT;Synthetic bone grafts for reconstruction of the jaw; surgical instruments for use in jaw reconstruction surgery, including surgical instruments for utilization to prepare a site in the jaw for a dental implant and for use in implanting a xenograft or biomaterial in the jaw;ATTACHMENT;
S.M.A.R.T.VERTICAL	Ernesto A. Lee, D.M.D., P.C.	976 Railroad Ave., Suite 200 Bryn Mawr PA 19010	Bone grafts using biological bone tissue for reconstruction of the jaw, including xenografts for use in reconstruction of the jaw;SMART VERTICAL;Synthetic bone grafts for reconstruction of the jaw; surgical instruments for use in jaw reconstruction surgery, including surgical instruments for utilization to prepare a site in the jaw for a dental implant and for use in implanting a xenograft or biomaterial in the jaw;
	Where the owner name is not linked, that owner no longer owns the brand

Technical Examples

An agent for treatment of metabolic bone disease, which contains EPO as an active ingredient, or a method for treating a patient with metabolic bone disease, which comprises EPO, is provided. Pharmaceutical products containing EPO as the active ingredient are novel prophylactic and therapeutic agents which show an ameliorative action by healing bone and bone marrow lesions in bone disease, especially bone disease based on impaired bone metabolism, aside from the previously reported erythrocyte increasing action of EPO. Pathological states, targeted by these pharmaceutical products, are bone diseases showing metabolic bone disorders, including renal failure-associated osteodystrophy, marble bone disease, diabetic nephropathy, and osteoporosis.